drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody; IL-2Rα antagonist)
drug_description
A humanized monoclonal antibody targeting the IL-2 receptor alpha subunit (CD25); blocks IL-2 binding and downstream JAK/STAT5 signaling to inhibit T-cell activation/proliferation and alloreactivity, and may deplete CD25+ cells via Fc effector functions. Used here to reduce GVHD and potentially affect CD25-expressing EBV-infected T/NK cells after allo-HSCT.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Daclizumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody against IL-2 receptor alpha (CD25) that blocks IL-2 binding and downstream JAK/STAT5 signaling, suppressing activation and proliferation of T cells (including alloreactive cells). May also deplete CD25+ cells through Fc-mediated effector functions such as ADCC/CDC.
drug_name
Recombinant humanized anti-CD25 monoclonal antibody
nct_id_drug_ref
NCT07029958